Latest news with #Paclitaxel
News18
7 days ago
- Health
- News18
This Rare Amazon Scorpion's Venom Can Kill Breast Cancer Cells, Say Scientists
Last Updated: Since extracting venom is impractical, scientists used Heterologous Expression to insert the gene into yeast, enabling large-scale production of the cancer-killing molecule In a groundbreaking discovery, Brazilian scientists have identified a molecule in the venom of the rare Amazon scorpion, Brotheas amazonicus, that shows promise in the treatment of breast cancer. This molecule, named BamazScplp1, has the remarkable ability to target and destroy cancer cells without harming normal cells in the body. Researchers at the University of São Paulo have drawn comparisons between BamazScplp1 and the traditional chemotherapy drug Paclitaxel, noting that initial lab tests demonstrate similar efficacy in eradicating breast cancer cells. BamazScplp1 is classified within the serine protease enzyme group, which is known for breaking down proteins and potentially disrupting the life cycle of cancer cells. The scientists observed that the molecule induces cancer cell death through necrosis, a process typically harmful to the body but potentially effective in eliminating tumours in cancer treatment. Given the impracticality of extracting venom directly from scorpions, the research team employed a biotechnological method known as Heterologous Expression. This technique involves inserting the relevant gene into a microorganism, such as yeast, to produce the molecule in large quantities. Professor Elian Arantes, the lead researcher, highlighted the use of the yeast Pichia pastoris, which is widely recognised in the biotech industry for its efficiency. This innovation allows for the mass production of BamazScplp1 without harming animals. Breast cancer remains the most common cancer among women worldwide and is the second leading cause of cancer-related deaths, according to the World Health Organization (WHO). In 2022, there were 2.3 million new cases and approximately 670,000 deaths attributed to breast cancer. Projections indicate that by 2050, these figures could rise to 3.2 million new cases and over 1 million deaths annually. The discovery of BamazScplp1 brings new hope in the fight against breast cancer. While the research is still in its preliminary stages, with extensive animal testing and clinical trials yet to come, the scientific community is optimistic about its potential. If BamazScplp1 proves to be as effective and safe in humans as it is in the lab, it could revolutionise the treatment of breast cancer. Get breaking news, in-depth analysis, and expert perspectives on everything from geopolitics to diplomacy and global trends. Stay informed with the latest world news only on News18. Download the News18 App to stay updated! First Published: June 25, 2025, 18:39 IST
Yahoo
29-05-2025
- Business
- Yahoo
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast cancer and metastatic adenocarcinoma of the pancreas More than 168,000 people live with metastatic breast cancer in the U.S., with only one-third of patients surviving 5 years after diagnosis1 Bringing paclitaxel to market underscores Meitheal's commitment to meeting patients' needs through a sustainable, affordable supply of critical medicines CHICAGO, May 29, 2025--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ("HKF"), paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane®2, in the U.S. The 100mg/vial single-dose presentation of protein-bound paclitaxel for injectable suspension is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas, and locally advanced or metastatic non-small cell lung cancer. "Many patients living with difficult-to-treat cancers are faced with the unfortunate reality that the complex, life-saving treatments they need are too expensive or unavailable. At Meitheal, we're committed to closing this gap – we believe that today's launch is critical to ensuring that cancer patients get the medicines they need," said Tom Shea, Chief Executive Officer of Meitheal. "We're excited to bring this to market in the U.S. and provide patients and providers with a reliable supply of an effective cancer care treatment." The launch of paclitaxel increases Meitheal's portfolio of on-market generic injectables to 68 products, and builds on Meitheal's successful 12 product launches in 2024. In addition to paclitaxel, Meitheal is planning to launch 20 new products this year across its core therapeutic areas as it continues to identify gaps in the marketplace and evaluate opportunities to address the needs of both patients and providers. ABOUT PACLITAXELPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a type of chemotherapy, interfering with microtubules and causing cancerous cells to die. Paclitaxel is largely used for the treatment of metastatic breast cancer, and additional types of cancer. IMPORTANT SAFETY INFORMATIONINDICATIONSPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. SELECT IMPORTANT SAFETY INFORMATION WARNING: SEVERE MYELOSUPPRESSIONSee full prescribing information for complete boxed warning. Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/ for neutropenia, which may be severe and result in infection or frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound).CONTRAINDICATIONSNeutrophil counts of < 1,500 cells/mm3; and severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). WARNINGS AND PRECAUTIONSSensory neuropathy occurs frequently and may require dose reduction or treatment interruption. Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1,500 cells/mm3, then resume treatment at reduced dose levels. Pneumonitis occurred with the use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. Severe hypersensitivity reactions with fatal outcome have been reported. Do not rechallenge with this drug. Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin derived from human blood, which has a theoretical risk of viral transmission. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ADVERSE REACTIONSThe most common adverse reactions (≥ 20%) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea. DRUG INTERACTIONSUse caution when concomitantly administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4. USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. This is not the complete list of all the safety information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Please click to see the full Prescribing Information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). ABOUT MEITHEAL PHARMACEUTICALS, in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 60 U.S. FDA-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of April 2025, Meitheal, directly or through its partners, has 30 products in the research and development phase, 16 additional products planned for launch in 2025, and 23 products under review by the FDA. Meitheal's mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers' needs. Ranked #2 in 2024 on Crain's Fast 50 in Chicago, and in the top 100 of Crain's Best Places to Work in Chicago from 2022 to 2024, Meitheal emulates the traditional Irish guiding principle we are named for—working together toward a common goal, for the greater good. Learn more about who we are and what we do at ABOUT HONG KONG KING-FRIEND INDUSTRIAL COMPANY (HKF)Hong Kong King-Friend Industrial Company is a wholly owned subsidiary of NKF, founded in 2010. ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF)Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three U.S. FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence in the U.S., China, EU and across the world. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over U.S. $3.0 billion. 1 Susan G. Komen Foundation. February 21, 2025. Metastatic Breast Cancer. 2 Abraxane® is a registered trademark of Celgene. View source version on Contacts MEDIA Meitheal Pharmaceuticals, Spilman, VP of Corporate Strategy773 899 5910info@
Yahoo
29-05-2025
- Business
- Yahoo
Meitheal Pharmaceuticals Announces Launch of Generic Paclitaxel Formulation in the United States Through Exclusive Commercial Licensing Agreement
Meitheal, through parent company Hong Kong King-Friend, launches generic paclitaxel Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast cancer and metastatic adenocarcinoma of the pancreas More than 168,000 people live with metastatic breast cancer in the U.S., with only one-third of patients surviving 5 years after diagnosis1 Bringing paclitaxel to market underscores Meitheal's commitment to meeting patients' needs through a sustainable, affordable supply of critical medicines CHICAGO, May 29, 2025--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has launched, through an exclusive license and supply agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. ("HKF"), paclitaxel protein-bound particles for injectable suspension (albumin-bound), a generic form of Abraxane®2, in the U.S. The 100mg/vial single-dose presentation of protein-bound paclitaxel for injectable suspension is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas, and locally advanced or metastatic non-small cell lung cancer. "Many patients living with difficult-to-treat cancers are faced with the unfortunate reality that the complex, life-saving treatments they need are too expensive or unavailable. At Meitheal, we're committed to closing this gap – we believe that today's launch is critical to ensuring that cancer patients get the medicines they need," said Tom Shea, Chief Executive Officer of Meitheal. "We're excited to bring this to market in the U.S. and provide patients and providers with a reliable supply of an effective cancer care treatment." The launch of paclitaxel increases Meitheal's portfolio of on-market generic injectables to 68 products, and builds on Meitheal's successful 12 product launches in 2024. In addition to paclitaxel, Meitheal is planning to launch 20 new products this year across its core therapeutic areas as it continues to identify gaps in the marketplace and evaluate opportunities to address the needs of both patients and providers. ABOUT PACLITAXELPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a type of chemotherapy, interfering with microtubules and causing cancerous cells to die. Paclitaxel is largely used for the treatment of metastatic breast cancer, and additional types of cancer. IMPORTANT SAFETY INFORMATIONINDICATIONSPaclitaxel protein-bound particles for injectable suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. SELECT IMPORTANT SAFETY INFORMATION WARNING: SEVERE MYELOSUPPRESSIONSee full prescribing information for complete boxed warning. Do not administer paclitaxel protein-bound particles for injectable suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/ for neutropenia, which may be severe and result in infection or frequent complete blood cell counts on all patients receiving paclitaxel protein-bound particles for injectable suspension (albumin-bound).CONTRAINDICATIONSNeutrophil counts of < 1,500 cells/mm3; and severe hypersensitivity reactions to paclitaxel protein-bound particles for injectable suspension (albumin-bound). WARNINGS AND PRECAUTIONSSensory neuropathy occurs frequently and may require dose reduction or treatment interruption. Sepsis occurred in patients with or without neutropenia who received paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; interrupt paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine until sepsis resolves, and if neutropenia, until neutrophils are at least 1,500 cells/mm3, then resume treatment at reduced dose levels. Pneumonitis occurred with the use of paclitaxel protein-bound particles for injectable suspension (albumin-bound) in combination with gemcitabine; permanently discontinue treatment with paclitaxel protein-bound particles for injectable suspension (albumin-bound) and gemcitabine. Severe hypersensitivity reactions with fatal outcome have been reported. Do not rechallenge with this drug. Exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment, consider dose reduction and closely monitor patients with hepatic impairment. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) contains albumin derived from human blood, which has a theoretical risk of viral transmission. Paclitaxel protein-bound particles for injectable suspension (albumin-bound) can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception. ADVERSE REACTIONSThe most common adverse reactions (≥ 20%) in metastatic breast cancer are alopecia, neutropenia, sensory neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, and diarrhea. DRUG INTERACTIONSUse caution when concomitantly administering paclitaxel protein-bound particles for injectable suspension (albumin-bound) with inhibitors or inducers of either CYP2C8 or CYP3A4. USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. This is not the complete list of all the safety information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Please click to see the full Prescribing Information for Paclitaxel protein-bound particles for injectable suspension (albumin-bound). ABOUT MEITHEAL PHARMACEUTICALS, in 2017 and based in Chicago, Meitheal is focused on the development and commercialization of generic injectable medications and, as of 2022, has expanded its focus to include fertility, biologic, and branded products. Meitheal currently markets over 60 U.S. FDA-approved products across numerous therapeutic areas including anti-infectives, oncolytics, intensive care, and fertility. As of April 2025, Meitheal, directly or through its partners, has 30 products in the research and development phase, 16 additional products planned for launch in 2025, and 23 products under review by the FDA. Meitheal's mission is to provide easy access to fairly priced products through robust manufacturing, consistent supply, and rapid response to our customers' needs. Ranked #2 in 2024 on Crain's Fast 50 in Chicago, and in the top 100 of Crain's Best Places to Work in Chicago from 2022 to 2024, Meitheal emulates the traditional Irish guiding principle we are named for—working together toward a common goal, for the greater good. Learn more about who we are and what we do at ABOUT HONG KONG KING-FRIEND INDUSTRIAL COMPANY (HKF)Hong Kong King-Friend Industrial Company is a wholly owned subsidiary of NKF, founded in 2010. ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF)Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three U.S. FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence in the U.S., China, EU and across the world. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over U.S. $3.0 billion. 1 Susan G. Komen Foundation. February 21, 2025. Metastatic Breast Cancer. 2 Abraxane® is a registered trademark of Celgene. View source version on Contacts MEDIA Meitheal Pharmaceuticals, Spilman, VP of Corporate Strategy773 899 5910info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-03-2025
- Business
- Yahoo
The Global Market for Paclitaxel Injections Presents an $11.17 Billion Revenue Opportunity by 2029 - Analysis of Key Players Pfizer, BMS, Fresenius Kabi Oncology, Abbott Labs, and Viatris Among Others
Paclitaxel Injection Market Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Paclitaxel Injection Market Report 2025"has been added to report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. The paclitaxel injection market size has grown rapidly in recent years. It will grow from $6.02 billion in 2024 to $6.87 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to clinical research and trials, increasing incidence of cancer, patient awareness and education, globalization of pharmaceutical paclitaxel injection market size is expected to see rapid growth in the next few years. It will grow to $11.17 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to personalized medicine approaches, biosimilar development, rising cancer burden in aging population, advancements in drug delivery systems, healthcare policy changes. Major trends in the forecast period include integration of ai in oncology, telemedicine and remote healthcare services, technological innovations in drug delivery, integration of drug delivery technologies, rise of anticipated rise in breast cancer cases is poised to drive the growth of the paclitaxel injection market in the future. According to the American Cancer Society's January 2023 estimate, approximately 297,790 new cases of invasive breast cancer are expected in the US, leading to an estimated 43,700 deaths in 2023. Thus, the increasing incidence of breast cancer is a significant factor propelling the growth of the paclitaxel injection increasing incidence of cancer is anticipated to drive the growth of the paclitaxel injection market in the future. For example, in May 2024, the National Cancer Institute, a US-based government agency focused on cancer research and training, projected that the global number of new cancer cases per year is expected to reach 29.9 million, along with 15.3 million cancer-related deaths by 2040. Therefore, the increasing incidence of cancer is propelling the growth of the paclitaxel injection companies in the paclitaxel injection market are focusing on developing innovative products using advanced materials, such as protein-bound particles, to deliver reliable services to consumers. For example, in April 2022, Apotex Corp, a US-based pharmaceutical firm, introduced Paclitaxel protein-bound particles for injection (albumin-bound), a generic alternative to Abraxane for the first-line treatment of locally advanced or metastatic non-small cell lung cancer and for metastatic breast cancer. This formulation is administered through intravenous infusion and was launched by American Regent, Inc. as an alternative to players in the paclitaxel injection market are also concentrating on developing innovative products, such as albumin-bound paclitaxel solutions, to broaden treatment options for patients with specific cancer types, offering potentially life-extending therapies. For instance, in May 2023, American Regent, Inc., a US-based injectable manufacturer, launched Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), providing an alternative to Abraxane. This groundbreaking product functions as a microtubule inhibitor for the treatment of metastatic breast cancer, non-small cell lung cancer, and metastatic adenocarcinoma of the pancreas. Its significance lies in the potential to offer a life-extending treatment option for patients while aiding the company's expansion into the oncology market, further underscoring the importance of domestically manufactured America was the largest region in the paclitaxel injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the paclitaxel injection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the paclitaxel injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Report Scope Markets Covered:1) By Type: Natural Paclitaxel; Semi-Synthetic Paclitaxel2) By Drug Strength: 10mg Or mL; 20mg Or mL; 30mg Or mL3) By Indication: Breast Cancer; Prostate Cancer; Testicular Cancer; Non-Small Cell Lung Cancer; Lung Cancer; Other Indications4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies5) By End User: Hospitals; Clinics; Cancer Research InstituteSubsegments:1) By Natural Paclitaxel: Paclitaxel From Pacific Yew Tree; Paclitaxel From Other Natural Sources2) By Semi-Synthetic Paclitaxel: Docetaxel (Taxotere); Other Semi-Synthetic VariantsKey Companies Profiled: Pfizer Inc.; Bristol-Myers Squibb Company; Fresenius Kabi Oncology Ltd.; Abbott Laboratories; Viatris Series: Five years historic and ten years Ratios of market size and growth to related markets, GDP proportions, expenditure per Segmentation: Country and regional historic and forecast data, market share of competitors, market Attributes Report Attribute Details No. of Pages 200 Forecast Period 2025-2029 Estimated Market Value (USD) in 2025 $6.87 Billion Forecasted Market Value (USD) by 2029 $11.17 Billion Compound Annual Growth Rate 12.9% Regions Covered Global Some of the major companies featured in this Paclitaxel Injection market report include: Pfizer Inc. Bristol-Myers Squibb Company Fresenius Kabi Oncology Ltd. Abbott Laboratories Viatris Inc. Teva Pharmaceutical Industries Limited Sandoz International GmbH Hospira Inc. Dr. Reddy's Laboratories Ltd. Apotex Inc. Intas Pharmaceuticals Ltd. Zydus Lifesciences Limited Torrent Pharmaceuticals Ltd. Luye Pharma Group Biological E Limited Alembic Pharmaceuticals Limited Khandelwal Laboratories Pvt. Ltd. Gland Pharma Limited Abraxis Bio Science Inc. Novasep Holding SAS Sagent Pharmaceuticals Inc. Hainan Haiyao Co Ltd. Accord Healthcare Ltd. Natco Pharma Limited Strides Pharma Science Limited Panacea Biotec Ltd. American Regent Inc. MSN Laboratories Pvt Ltd. Hetero Drugs Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Paclitaxel Injection Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
